Pacira BioSciences is a drug manufacturers - specialty & generic business based in the US. Pacira BioSciences shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.38 – an increase of 4.7% over the previous week. Pacira BioSciences employs 711 staff and has a trailing 12-month revenue of around $695 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $17.38 |
|---|---|
| 52-week range | $11.16 - $35.95 |
| 50-day moving average | $15.75 |
| 200-day moving average | $23.13 |
| Wall St. target price | $18.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.97 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $17.03 from 2024-11-20
| 1 week (2024-11-15) | 2.59% |
|---|---|
| 1 month (2024-10-23) | -2.01% |
| 3 months (2024-08-22) | 21.90% |
| 6 months (2024-05-22) | -44.56% |
| 1 year (2023-11-22) | -36.19% |
|---|---|
| 2 years (2022-11-22) | -64.72% |
| 3 years (2021-11-22) | 54.6 |
| 5 years (2019-11-22) | 44.23 |
Valuing Pacira BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacira BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pacira BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $178 million.
The EBITDA is a measure of a Pacira BioSciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $695 million |
|---|---|
| Operating margin TTM | 13.02% |
| Gross profit TTM | $393.2 million |
| Return on assets TTM | 4.17% |
| Return on equity TTM | -11.48% |
| Profit margin | -13.06% |
| Book value | $16.24 |
| Market Capitalization | $760 million |
TTM: trailing 12 months
We're not expecting Pacira BioSciences to pay a dividend over the next 12 months.
Over the last 12 months, Pacira BioSciences's shares have ranged in value from as little as $11.164 up to $35.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira BioSciences's is 0.818. This would suggest that Pacira BioSciences's shares are less volatile than average (for this exchange).
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.